Imagen de Portada

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials

Fuente: arXiv

Guardado en:

Detalles Bibliográficos
Autores principales:	Komaki, Moka, Shinoda, Satoru, Zheng, Haiyan, Yamamoto, Kouji
Formato:	Preprint
Publicado:	2025
Materias:	Methodology Applications
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
por: Moka Komaki, et al.
Publicado: (2026)

Extension of Dynamic Network Biomarker using the propensity score method: Simulation of causal effects on variance and correlation coefficient
por: Shinoda, Satoru, et al.
Publicado: (2025)

BMW: Bayesian Model-Assisted Adaptive Phase II Clinical Trial Design for Win Ratio Statistic
por: Zhu, Di, et al.
Publicado: (2026)

Optimal Bayesian predictive probability for delayed response in single-arm clinical trials with binary efficacy outcome
por: Yoshimoto, Takuya, et al.
Publicado: (2024)

Two-stage Adaptive Design Cluster Randomised Trials
por: Watson, Samuel I., et al.
Publicado: (2026)

SIMBA -- A Bayesian Decision Framework for the Identification of Optimal Biomarker Subgroups for Cancer Basket Clinical Trials
por: Yuan, Shijie, et al.
Publicado: (2025)

A Bayesian Discrete Framework for Enhancing Decision-Making Processes in Clinical Trial Designs and Evaluations
por: Pramanik, Paramahansa, et al.
Publicado: (2026)

BOIN Designs for Dose Escalation With Selected Dose Combinations in Oncology Phase I Trials
por: Chen, Yuxuan, et al.
Publicado: (2026)

Implementing Response-Adaptive Randomisation in Stratified Rare-disease Trials: Design Challenges and Practical Solutions
por: Das, Rajenki, et al.
Publicado: (2024)

MUCE: Bayesian Hierarchical Modeling for the Design and Analysis of Phase 1b Multiple Expansion Cohort Trials
por: Lyu, Jiaying, et al.
Publicado: (2020)

A Workflow for Evaluating Regional Treatment Effect Heterogeneity in Multi-Regional Clinical Trials
por: Zhang, Cong, et al.
Publicado: (2026)

Robust Bayesian hierarchical models for basket trials enabling joint evaluation of toxicity and efficacy
por: Cao, Zhi, et al.
Publicado: (2025)

On the Calibration of Bayesian Success Criteria and Operating Characteristics for Clinical Trials
por: Yang, Peng, et al.
Publicado: (2026)

Bayesian Design and Analysis of Precision Trials with Partial Borrowing
por: Golchi, Shirin, et al.
Publicado: (2026)

Optimal sequential two-stage Bayes Factor Design for two-arm clinical Phase II Trials with binary Endpoints
por: Kelter, Riko
Publicado: (2026)

Identifying Treatment Effect Heterogeneity with Bayesian Hierarchical Adjustable Random Partition in Adaptive Enrichment Trials
por: Zhao, Xianglin, et al.
Publicado: (2025)

Priors from Envisioned Posterior Judgments: A Novel Elicitation Approach With Application to Bayesian Clinical Trials
por: Ouyang, Yongdong, et al.
Publicado: (2024)

Bayesian sample size determination using robust commensurate priors with interpretable discrepancy weights
por: Whitehead, Lou E., et al.
Publicado: (2024)

Dynamic Prediction of the Target Survival Time in Metastatic Solid Tumor Cancer Clinical Trials
por: Wang, Sidi, et al.
Publicado: (2026)

A Bayesian Optimal Phase II Design for Randomized Immunotherapy Trials with Delayed Treatment Effects
por: Cai, Zhongheng, et al.
Publicado: (2025)

Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
por: Lee, Kyong Ju, et al.
Publicado: (2025)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I-II Oncology Dose Finding Trials
por: Hall, Andrew, et al.
Publicado: (2025)

Power and Sample Size Calculations for Bayes Factors in two-arm clinical Phase II Trials with binary Endpoints
por: Kelter, Riko
Publicado: (2026)

A Seamless Phase II/III Design with Dose Optimization for Oncology Drug Development
por: Li, Yuhan, et al.
Publicado: (2024)

Statistical Inference for Heterogeneous Treatment Effect with Right-censored Data from Synthesizing Randomized Clinical Trials and Real-world Data
por: Mao, Guangcai, et al.
Publicado: (2025)

Uncovering Treatment Effect Heterogeneity in Pragmatic Gerontology Trials
por: Li, Changjun, et al.
Publicado: (2025)

A Clustering Approach for Basket Trials Based on Treatment Response Trajectories
por: Kojima, Masahiro, et al.
Publicado: (2025)

Bayesian Spatial Point Process Modeling for Cluster Randomized Trials
por: Lee, Jooyeon, et al.
Publicado: (2025)

[Invited Discussion] Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions
por: Phillips, Rachael V., et al.
Publicado: (2024)

A Unified Bayesian Framework for Mortality Model Selection
por: Diana, Alex, et al.
Publicado: (2024)

A Causal Machine Learning Framework for Treatment Personalization in Clinical Trials: Application to Ulcerative Colitis
por: Minoccheri, Cristian, et al.
Publicado: (2026)

Personalized Treatment Hierarchies in Bayesian Network Meta-Analysis
por: Wigle, Augustine, et al.
Publicado: (2026)

A Bayesian Framework for Latent Compliance Modeling in Cluster Randomized Trials with One-Sided Noncompliance
por: Sisti, Anthony, et al.
Publicado: (2025)

Heterogeneous Clinical Trial Outcomes via Multi-Output Gaussian Processes
por: Thomas, Owen, et al.
Publicado: (2024)

E-values for Adaptive Clinical Trials: Anytime-Valid Monitoring in Practice
por: Sokolova, Alexandra, et al.
Publicado: (2026)

Fragility Index for Time-to-Event Endpoints in Single-Arm Clinical Trials
por: Maity, Arnab Kumar, et al.
Publicado: (2024)

Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials
por: Long, James P., et al.
Publicado: (2025)

A Bayesian Hybrid Design with Borrowing from Historical Study
por: Lu, Zhaohua, et al.
Publicado: (2024)

Bayesian Network Propensity Score to Evaluate Treatment Effects in Observational Studies
por: Di Serio, Clelia, et al.
Publicado: (2025)

Correcting for Missing Data When Evaluating Surrogate Markers in a Clinical Trial
por: Lotspeich, Sarah C., et al.
Publicado: (2026)